Migration inhibitory factor (MIF) has been shown to be critical in the pathology of early artherosclerosis; this article aim to investigate the plasma levels of MIF in hypertension plus hyperlipidemia patients.
Introduction
Hypertension-hyperlipidemia (HTN-HLP) is the most common combination of chronic conditions among Medicare beneficiaries in USA, [1] counting for 56% men and 53.5% women in patients >65 years old. In China, there were about 180 million people with hypertension and 70 million people with hyperlipidemia in 2008. [2] Although the number of patients suffered from both hypertension and hyperlipidemia is not yet clear, we could see that the burden of HTN-HLP is significant. Moreover, hypertension and hyperlipidemia as independent risk factors for coronary heart disease (CHD) could accelerate the progression of artherosclerosis and CHD. HTN caused endothelial dysfunction in patient, [3] [4] [5] [6] [7] probably by upregulating adhesion molecules ICAM-1 (intercellular adhesion molecule-1) and VCAM-1 (vascular cell adhesion molecule-1), [8] which may promote endothelium-leukocyte adhesion and inflammation. [9, 10] HLP contributes to endothelial dysfunction accompanied by the expression of adhesion molecules and chemokines and thereby leads to early subintimal infiltration with mononuclear cells. [11, 12] However, the exact impacts of HTN-HLP on endothelial function and underlying mechanism has not been fully elucidated.
The migration inhibitory factor (MIF) is a highly conserved cytokine with proven impacts in acute myocardial infarction.
The expression of MIF has also been shown to correlate with increased intima-media thickening and lipid deposition in human carotid artery plaques, [14] indicating critical roles in early artherosclerosis. Hypertension and hyperlipidemia are both important risk factors of artherosclerosis [10] ; it is possible that MIF played indispensable roles in the pathogenesis of HTN-HLP. Unfortunately, such involvement has not been shown. MIF was elevated in the aorta of patients with hypertension as well as coronary artherosclerosis, [15] with serum MIF levels higher in women with metabolic syndrome than in healthy subjects. [16] MIF was also found to promote endothelial expressions of ICAM-1 and VCAM-1. [17, 18] However, to our best knowledge, there is no report on the serum level of MIF in patients with hyperlipidemia or hypertension. Here in this article, we will compare plasma MIF levels between HTN-HLP patients and healthy adults (HEALTHY) and discuss its correlation with clinical characteristics, artherosclerosis parameters, and endothelial function markers.
Materials and methods

Study subjects
This is a mono-center retrospective case-control study. The study subjects were selected in the out-patient department in Peking University Third Hospital from 1st January 2014 to 31st December 2014. There were 39 patients enrolled as the HTN-HLP group. The inclusion criteria were age 30 to 60 years; newly diagnosed grade 1 to 2 hypertension [19] plus hyperlipidemia [20] without any previous treatment. Exclusion criteria were diabetes mellitus, aspirin administration in the past 2 weeks, cardiac or cerebral ischemic vascular diseases, impaired hepatic and renal function and other major or acute pathologies. Secondary hypertension was excluded by routine diagnostic procedures. Twenty-five gender and agematched healthy subjects without any previous medical history were enrolled as healthy control group (HEALTHY). Each participants were assigned a randomized research number, and authors had no access to personal information that could identify individual participants during or after data collection. The protocol was approved by institutional guidelines of the Ethics Committee of Peking University Third hospital (IRB00006761 -2011096(2)). All subjects were aware of the investigational nature of the study and gave their written consents.
Laboratory and bioanalytical procedures
Routine laboratory tests including blood HCT (red blood cell specific volume), WBC (white blood cell), PLT (platelet), Scr (serum creatinine), BUN (blood urea nitrogen), UA (uric acid), FBG (fasting blood glucose), HbA1c (glycosylated hemoglobin), HDL-C (high-density lipoprotein-cholesterol), ApoA1 (apolipoprotein A-1), Lp-a (lipoprotein-a), TCHO (total cholesterol), LDL-C (low density lipoprotein-cholesterol), TG (triglyceride), ApoB (apolipoprotein B), Hs-CRP (high sensitivity-C reactive protein), serum ALT (alanine aminotransferase), and AST (aspartate aminotransferase) were determined by the standard laboratory methods immediately after sampling in HTN-HLP and HEALTHY groups.
Assessment of baPWV and ABI
Brachial-ankle pulse wave velocity (baPWV) and ankle brachial index (ABI) were measured using a volume-plethymographic apparatus (BP203RPE-III; Omron-Colin, Japan). Participants were rested in the supine position for at least 15 minutes. Pneumatic pressure cuffs were placed snugly around both arms and both ankles.
Assessment of CIMT
The carotid intima-media thickness (CIMT) was measured using B-mode ultrasound and a 7.5 MHz transducer. Intimal-medial thickness was defined as the distance between the leading edge of the first echogenic line (lumen-intima interface) and the second echogenic line (media-adventitia interface) of the far wall. Measurements were taken from 0.5 to 2 cm below the carotid bifurcation of the common carotid artery on each side, and their means were calculated as the intimal-medial thickness. All the CIMT measurements were performed by a single radiologist.
Measurement of MIF
Blood samples were drawn by venipuncture into vacationer tubes containing heparin lithium. Plasma was isolated from whole blood by centrifugation and kept in -80°C until experiment in March 2015. Plasma MIF was measured in duplicates using Quantikine MIF ELISA kits (DMF00B, R&D Systems) according to manufacturer's specifications.
Measurement of NO, eNOS, and ET-1
Serum was isolated from whole blood by centrifugation. Serum nitric oxide (NO), endothelial nitric oxide synthase (eNOS), and endothelin (ET-1) was measured in duplicates using ELISA (BD Biosciences) according to manufacturer's specifications. Thirtytwo of the 39 HTN-HLP patients and all 25 of the healthy adults consented to examine NO, eNOS, and ET-1.
Culture of HUVEC
Human umbilical vein endothelial cells (HUVEC) were collected from human umbilical cord veins obtained from Peking University Third Hospital Obstetrics and Gynecology department. HUVECs were cultured in Endothelial Cell Medium (ECM) (Sciencell, American) which contained essential and nonessential amino acids, vitamins, Penicillin, organic and inorganic compounds, hormones, growth factors, streptomycin, trace minerals, and a low concentration of fetal bovine serum (FBS) (5%) at 37°C in humidified air containing 5% CO 2 . The cells were expanded and frozen to provide enough cells. The cells were used from 3 to 5 passages in this experiment.
Examination of VCAM-1 and ICAM-1 expression on HUVEC
HUVECs were cultured in 96-well plates and cultured to ∼80% confluent. After 12 hours of starvation with serum-free ECM, the cells were treated with 100 mL fresh ECM plus 100 mL pooled plasma from HEALTHY or HTN-HLP groups and cultured for 6 hours. Expression of VCAM-1 or ICAM-1 on the surface of HUVECs was examined by ELISA as previously described. [21] Briefly, cells were washed with PBS twice and fixed with PBS containing 4% paraformaldehyde at room temperature. The plates were blocked with 2% BSA at 37°C for 2 hours. Expression of VCAM-1or ICAM-1 were determined by means of primary binding with specific antibody (sc-8304& sc-7891, Santa Cruz), followed by secondary binding with an HRP-conjugated goat anti-rabbit IgG antibody. Quantification was performed by 
Results
The clinical characteristics of hypertension-hyperlipidemia and healthy groups
The demographic, biochemical, and clinical data as well as endothelial function of hypertension-hyperlipidemia (HTN-HLP) and healthy control (HEALTHY) groups were listed in Table 1 . Two groups did not differ in regard to gender, age, BMI (body mass index), smoking, heart rates, blood HCT, WBC, PLT, Scr, BUN, UA, FBG, HbA1c, HDL-C, ApoA1, Lp-a, and left ABI. However, SBP (systolic blood pressure), DBP (diastolic blood pressure), TCHO, LDL-C, TG, ApoB, Hs-CRP, left and right average IMT, left and right baPWV, right ABI and Framingham risk score were significantly higher in the HTN-HLP group comparing with the HEALTHY group.
Plasma MIF was elevated and endothelial function was impaired in HTN-HLP patients
Plasma MIF was measured using ELISA kits as described previously. [23] As shown in Fig. 1A , MIF was significantly elevated in the HTN-HLP group comparing with the HEALTHY group (65.60 ± 44.35ng/mL vs 26.63 ± 10.85ng/mL, P < 0.001). Key markers of endothelial function were also examined in the serum of both groups. [24] As shown in Fig. 1B and C, serum NO (19.10 ± 1.71 nmol/mL vs 33.82 ± 2.50 nmol/mL, P < 0.001) and eNOS (17.68 ± 1.85 U/mL vs 31.25 ± 2.77 U/mL, P < 0.001) levels were significantly lower in the HTN-HLP group comparing with the HEALTHY group. Serum ET-1 levels were significantly higher in the HTN-HLP group comparing with the HEALTHY group (95.44 ± 3.16 ng/mL vs 43.15 ± 3.09 ng/mL, P < 0.001).
3.3. Plasma MIF was correlated with blood pressure, PWV, cholesterol levels, and endothelial function
In order to find the influencing factor of MIF, we performed correlation analysis between plasma MIF levels and clinical characteristics in general population (including HTN-HLP and HEALTHY groups). As shown in Table 2 and Fig. 2 , SBP (R 2 = 0.198, P < 0.001), DBP (R 2 = 0.216, P < 0.001), left baPWV (R 2 = 0.122, P = 0.007), right baPWV (R 2 = 0.129, P = 0.005), and ET-1 (R 2 = 0.248, P < 0.001) were significantly positively correlated with plasma MIF levels, NO (R 2 = -0.184, P < 0.001) and eNOS (R 2 = -0.230, P < 0.001) were significantly negatively correlated with plasma MIF levels in general population.
To further distinguish the affecting factor of MIF in HTN-HLP patients, we performed correlation tests between plasma MIF levels and clinical characteristics in the HTN-HLP group. As shown in Table 3 and Fig. 3 , TCHO (R 2 = -0.200, P = 0.006), 
Plasma from HTN-HLP patients promoted endothelial adhesion molecules expression
To explore the functional significance of elevated plasma MIF in HTN-HLP patients, we treated HUVECs with pooled plasma from HTN-HLP and HEALTHY groups. The protein levels of adhesion molecules VCAM-1 and ICAM-1 were determined by ELISA as described previously. [21] As shown in Fig. 4 , plasma from HTN-HLP patients significantly stimulated VCAM-1(P = 0.002) and ICAM-1 (P = 0.01) protein expression, comparing with plasma from healthy adults.
Discussion
Hypertension and hyperlipidemia as independent risk factors for coronary heart disease (CHD) could cause endothelial dysfunction by upregulating adhesion molecules ICAM-1 and VCAM-1. [9] [10] [11] [12] 25, 26] MIF has been found elevated in acute myocardial infaction and CHD patients [13, 15, 23] ; recent reports also indicated potential roles of MIF in the pathology of metabolic syndrome. [16] However, the impacts of HTN-HLP on endothelial function and underlying mechanism has not been fully elucidated; also there is no report on the serum level of MIF in HTN-HLP patients. Here in this article we hypothesized HTN-HLP patients may have elevated plasma MIF levels, which may stimulate the expression of ICAM-1 and VCAM-1, thus causing endothelial dysfunction.
We found that MIF was significantly elevated in the plasma of HTN-HLP patients (Fig. 1A) . It was reported that MIF promoted endothelial expressions of ICAM-1 and VCAM-1and monocyte adhesion. [17, 18] Thus, we asked whether treatment with plasma and ET-1(D) were measured using ELISA and compared between HTN-HLP and HEALTHY groups. * * * P < 0.001. eNOS = endothelial nitric oxide synthase, ET-1 = endothelin, HEALTHY = healthy adults, HTN-HLP = hypertension-hyperlipidemia, MIF = migration inhibitory factor, NO = nitric oxide. Table 2 Correlation between plasma MIF, clinical characteristics, and endothelial function in general population. from HTN-HLP patients could promote endothelial expression of ICAM-1 and VCAM-1. We found that plasma from HTN-HLP patients significantly promoted ICAM-1 and VCAM-1 protein levels on the surface of HUVECs. To our best knowledge, no study has reported the influence of plasma from HTN-HLP patients on endothelial adhesion molecule expression. Our findings indicated elevated plasma MIF levels may be responsible for impaired endothelial function in HTN-HLP patients.
In this study, we also discussed the correlation of plasma MIF with clinical characteristics, endothelial function, and atherosclerosis parameters. In general population, we found that SBP, DBP, left baPWV, right baPWV, and ET-1 levels were significantly positively; NO and eNOS levels were significantly negatively correlated with plasma MIF levels. These results indicated that plasma MIF may be elevated in patients with hypertension, especially with target organ damage (arterial stiffness) and impaired endothelial function. To our surprise, we found that TCHO, LDL-C, and ApoB were all significantly negatively correlated with plasma MIF levels in HTN-HLP patients. These results indicated that in HTN-HLP patients higher cholesterol levels may not necessarily elevate plasma MIF levels. In fact, report showed that MIF gene variation rather than plasma MIF level was correlated with cholesterol levels in human, [27] whereas animal study found that knockdown of MIF gene did not change serum cholesterol levels. [28] MIF is widely expressed by different cell types, including monocytes, macrophages, T-cells, dendritic cells, mast cells, mesenchymal cells, endothelial cells, and cardiomyocytes. [29] Thus, MIF released from cardiomyocytes (cardiogenic MIF) or immune plasma and endothelial cells (noncardiogenic MIF) could both be detected in plasma. [30] Cardiogenic MIF was detected in the plasma of acute myocardial infarction patients, accompanied with elevated levels of cardiac injury markers. [23] Here we detected elevated plasma MIF levels but not cardiac injury markers in HTN-HLP patients, which was probably noncardiogenic MIF. However, the current technique could not determine the cell-origin of plasma MIF, which was 1 limitation of this search. Another limitation of this work was that this was a mono-center retrospective study involving only Chinese population, which needs to be examined in other centers of different races. ABI = ankle brachial index, ApoA1 = apolipoprotein A-1, ApoB = apolipoprotein B, baPWV = brachial-ankle pulse wave velocity, BMI = body mass index, BUN = blood urea nitrogen, DBP = diastolic blood pressure, eNOS = endothelial nitric oxide synthase, ET-1 = endothelin, HbA1c = glycosylated hemoglobin, HCT = red blood cell specific volume, HDL-C = high density lipoproteincholesterol, Hs-CRP = high sensitivity-C reactive protein, LDL-C = low density lipoprotein-cholesterol, Lp-a = lipoprotein-a, MIF = migration inhibitory factor, NO = nitric oxide, PLT = platelet, SBP = systolic blood pressure, Scr = serum creatinine, Scr = serum creatinine, TCHO = total cholesterol, TG = triglyceride, UA = uric acid, WBC = white blood cell. 
Conclusion
Although our results need to be confirmed by large-scale studies, we found that plasma MIF was elevated in HTN-HLP patients and correlates with impaired endothelial function. MIF may act as a potential marker for endothelial function in hypertension and hyperlipidemia patients in future. 
